关于[18F]FDOPA PET/CT 作用的最新进展。

IF 4.6 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Gilles N Stormezand, Eline de Meyer, Klaas Pieter Koopmans, Adrienne H Brouwers, G Luurtsema, Rudi A J O Dierckx
{"title":"关于[18F]FDOPA PET/CT 作用的最新进展。","authors":"Gilles N Stormezand, Eline de Meyer, Klaas Pieter Koopmans, Adrienne H Brouwers, G Luurtsema, Rudi A J O Dierckx","doi":"10.1053/j.semnuclmed.2024.09.004","DOIUrl":null,"url":null,"abstract":"<p><p>[<sup>18</sup>F]-dihydroxyphenylalanine ([<sup>18</sup>F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [<sup>18</sup>F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [<sup>18</sup>F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [<sup>18</sup>F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Update on the Role of [<sup>18</sup>F]FDOPA PET/CT.\",\"authors\":\"Gilles N Stormezand, Eline de Meyer, Klaas Pieter Koopmans, Adrienne H Brouwers, G Luurtsema, Rudi A J O Dierckx\",\"doi\":\"10.1053/j.semnuclmed.2024.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>[<sup>18</sup>F]-dihydroxyphenylalanine ([<sup>18</sup>F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [<sup>18</sup>F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [<sup>18</sup>F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [<sup>18</sup>F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.</p>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1053/j.semnuclmed.2024.09.004\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2024.09.004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

[18F]-二羟基苯丙氨酸([18F]FDOPA)是一种放射性药物,可用于多种疾病,包括神经内分泌肿瘤(NET)、先天性高胰岛素血症、帕金森综合征和神经肿瘤。基因分析和疾病特异性生物标志物可指导在几种神经内分泌肿瘤和先天性高胰岛素血症的不同阶段对可能从[18F]FDOPA PET中获益最多的患者进行最佳选择。在神经肿瘤学的临床常规治疗中,[18F]FDOPA PET 的适应症包括肿瘤分界以及区分治疗相关变化和复发疾病。随着大轴向视野 PET/CT 或 PET/MRI 集成系统的出现,新的发展可能会提供更多独特的机会,如在 NET 的原发分期中检测较小的病灶、减少先天性高胰岛素血症儿童的剂量,或通过使用图像衍生输入函数获得更广泛的无创量化脑摄取的可能性。虽然[18F]FDOPA 的广泛应用过去一直受到复杂合成方法和高生产成本的阻碍,但现在人们已经做出了巨大努力,以提供具有高活性产率和摩尔活性的符合 GMP 标准的可靠合成方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Update on the Role of [18F]FDOPA PET/CT.

[18F]-dihydroxyphenylalanine ([18F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [18F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [18F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [18F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Seminars in nuclear medicine
Seminars in nuclear medicine 医学-核医学
CiteScore
9.80
自引率
6.10%
发文量
86
审稿时长
14 days
期刊介绍: Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信